{
    "title": "109_s2300",
    "content": "The Act may be cited as the \"Lower Prices Reduced with Increased Competition and Efficient Development of Drugs Act\" or the \"Lower PRICED Drugs Act\". It includes provisions for generic drug use certification. The Lower PRICED Drugs Act amends the Federal Food, Drug, and Cosmetic Act regarding antibiotic drug labeling for listed drug products. The Lower PRICED Drugs Act amends the Federal Food, Drug, and Cosmetic Act by requiring a statement in abbreviated new drug applications identifying relevant patents and approved uses, and clarifying the effective date of the amendments. SEC. 3. PREVENTING ABUSE OF THE THIRTY-MONTH STAY-OF-EFFECTIVENESS PERIOD. SEC. 3 amends the Federal Food, Drug, and Cosmetic Act to ensure proper use of the thirty-month stay-of-effectiveness period. The court will consider various factors in determining whether to shorten the period. The amendments apply to any stay pending or filed after the enactment of the Act. The Federal Food, Drug, and Cosmetic Act is amended to change \"drug\" to \"drug product\" in various sections. Additionally, market exclusivity for new drugs is modified to include specific information for pediatric patients based on study results. The Federal Food, Drug, and Cosmetic Act is amended to change \"drug\" to \"drug product\" in various sections, including provisions related to pediatric patients and market exclusivity for new drugs. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products, including market exclusivity for already-marketed drugs. The amendments involve changes in the listing of patents based on pediatric study submissions to the FDA. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products. The amendments involve changes in the listing of patents based on pediatric study submissions to the FDA, including specific requirements for labeling with therapeutically meaningful information for pediatric patients. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products. The amendments involve changes in the listing of patents based on pediatric study submissions to the FDA, including specific requirements for labeling with therapeutically meaningful information for pediatric patients. Amendments include adjustments to subsections and clauses regarding patent listings and pediatric study approvals. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products. The amendments involve changes in the listing of patents based on pediatric study submissions to the FDA, including specific requirements for labeling with therapeutically meaningful information for pediatric patients. Amendments include adjustments to subsections and clauses regarding patent listings and pediatric study approvals, such as updating the criteria for listed patents. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products, including changes to the exclusivity period from six months to three months. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products, including changes to the exclusivity period. Section 505A is amended to define \"drug product\" and specify that each dosage form constitutes a different drug product. The Federal Food, Drug, and Cosmetic Act is amended to update provisions related to pediatric studies and patents for drug products. Section 505A is amended to specify that each dosage form constitutes a different drug product, with technical corrections made to subsections (c)(3)(D) and (n). The amendments apply to requests for pediatric studies after the enactment of the Act. SEC. 5. CITIZEN PETITIONS AND PETITIONS FOR STAY OF AGENCY ACTION. Section 505 of the Federal Food, Drug, and Cosmetic Act is amended to address Citizens Petitions and Petitions for Stay of Agency Action. The Secretary is not allowed to delay approval of applications while petitions are reviewed. Final agency action on a petition must be taken within six. The Secretary must take final agency action on a petition within six months of receipt. If no action is taken by this deadline, the petition is deemed denied. The petition must be signed and verified before being accepted for review. The petition must include representative data and information unfavorable to the petition, and the petitioner must certify that all relevant information was disclosed. The thirty-month period for petition review may be extended based on certain circumstances. The thirty-month period for petition review may be extended based on the time that lapses from the date the Secretary receives a petition to the date of final agency action, regardless of the outcome of the petition."
}